ADP-A2M4CD8 as Monotherapy or in Combination With Either Nivolumab or Pembrolizumab in HLA-A2+ Subjects With MAGE-A4 Positive Tumors (SURPASS)
NCT04044859 is a phase 1 interventional trial sponsored by USWM CT, LLC. As of 21 Nov 2026, it is active and no longer recruiting. It studies Endometrial Cancer, Esophageal Cancer and 7 more conditions. The registry lists an enrollment of 120 participants at 17 sites in 3 countries. The registry lists a start date of 20 Aug 2019 and a primary completion date of 15 Apr 2026. One of its registered investigators has a FindMyKOL profile.
Key facts
Registry attributes as recorded on the ClinicalTrials.gov study record.
| Field | Value |
|---|---|
| Registry ID | NCT04044859 |
| Status | Active not recruiting |
| Phase | Phase 1 |
| Study type | Interventional trial |
| Lead sponsor | USWM CT, LLC |
| Enrollment | 120 |
| Registered sites | 17 |
| Countries | 3 |
| Conditions | Endometrial Cancer, Esophageal Cancer, Esophagogastric Junction (EGJ), Gastric (Stomach) Cancer, Head and Neck Cancer, Melanoma and 3 more conditions |
| Start | 20 Aug 2019 |
| Primary completion | 15 Apr 2026 |
| Study completion | 30 Apr 2037 |
| Last update posted | 23 Sept 2026 |
Registered summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
17 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Name of Institution: Orlando Health Cancer Institute
Orlando
- Massachusetts General Hospital
Boston
- Washington University - School of Medicine
St Louis
- Memorial Sloan Kettering Cancer Center
New York
- Duke University Medical Center, Duke Cancer Institute
Durham
- Ou Health Stephenson Cancer Center
Oklahoma City
- Sarah Cannon Research Institute
Nashville
- M.D. Anderson Cancer Center
Houston
- Froedtert Hospital and the Medical College of Wisconsin
Milwaukee
- Hospital Universitario 12 de Octubre
Madrid, Avenida de Cordoba S/n
- Clinica Universitaria de Navarra
Pío, Pamplona
- Hospital Clinico de Valencia
Ibanez, Valencia
- Hospital Universitario Vall D'Hebron
Barcelona
- Hospital Universitario Fundacion Jimenez Diaz
Madrid
- Hospital Universitario Hm Sanchinarro Ciocc
Madrid
- Hospital Universitario Virgen del Rocio
Seville
- Princess Margaret Cancer Centre
Toronto, Ontario
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study. It may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Questions about NCT04044859
Each answer restates registry values shown on this page.
What is NCT04044859?
NCT04044859 is a phase 1 interventional trial sponsored by USWM CT, LLC. It studies Endometrial Cancer, Esophageal Cancer and 7 more conditions.
Is NCT04044859 recruiting?
As of 21 Nov 2026, it is active and no longer recruiting.
Who leads NCT04044859?
The registry names David Hong, MD (principal investigator, M.D. Anderson Cancer Center) as the overall official.
Where does NCT04044859 run?
The registry lists 17 sites in 3 countries. Most sites are in these countries: United States (9), Spain (7) and Canada (1).
When is NCT04044859 expected to complete?
The registry lists a primary completion date of 15 Apr 2026 and a study completion date of 30 Apr 2037. The sponsor last updated the record on 23 Sept 2026.
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 21 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.